Moderna COVID-19 Vaccine: Mechanisms, Efficacy, Safety, and Future Directions

Shiqing Li[1, *]

[1] School of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, China

*Corresponding author: 202221140066@njtech.edu.cn

Abstract. This review examines the mechanisms, efficacy, safety, and future potential of the Moderna COVID-19 vaccine, a pioneering mRNA-based immunization. Utilizing lipid nanoparticle (LNP) delivery system, the vaccine delivers synthetic mRNA encoding the SARS-CoV-2 spike protein, initiating a robust immune response. The Phase III COVE trial demonstrated its remarkable efficacy, with an over 90% protection rate and significant prevention of severe cases. However, its effectiveness against variants like Omicron is reduced, though booster shots can enhance protection. In terms of safety, common reactions are mostly transient, but rare risks such as anaphylaxis and myocarditis/pericarditis require monitoring. The vaccine's durability shows a decline in antibody titers after six months, yet immune memory cells provide long-term defense. Despite limitations like strict cold chain requirements and challenges posed by viral variants, the Moderna vaccine's success paves the way for broader mRNA vaccine applications. Future research may focus on developing broad - spectrum vaccines, room - temperature - stable formulations, exploring mucosal immunization routes, and expanding to other fields like cancer immunotherapy. Overall, the Moderna vaccine represents a significant breakthrough in mRNA technology, with promising potential for addressing global health challenges beyond the COVID-19 pandemic.

Keywords: Moderna Vaccine, Lipid Nanoparticle Delivery, Vaccine Efficacy, Safety Profile, Future Perspectives.

1. Introduction

The Moderna COVID-19 vaccine emerged as a critical advancement in the global fight against the pandemic, marking a major milestone in vaccine development. As the world faced unprecedented challenges from SARS-CoV-2, the urgent need for effective vaccines led to the rapid advancement of mRNA technology, which had been under investigation for decades but had not previously been approved for human use. Moderna's mRNA-1273 vaccine represented a breakthrough, leveraging synthetic messenger RNA to instruct cells to produce the SARS-CoV-2 spike protein, thereby triggering an immune response without using live or inactivated virus. This innovative approach allowed for faster development compared to traditional vaccine methods, with the entire process—from sequence identification to clinical trials—completed in under a year [1, 2].

The mRNA platform's flexibility proved especially valuable as new variants of the virus emerged. Unlike conventional vaccines, which often require time-consuming adjustments to production processes, mRNA vaccines can be quickly modified by updating the genetic sequence to match evolving viral strains. This flexibility positions mRNA technology as a promising and scalable solution not only for COVID-19 but also for future infectious diseases and even cancer immunotherapy [3, 4]. The success of Moderna’s vaccine underscored the transformative potential of mRNA to revolutionize vaccine development, offering a rapid and adaptable response to global health threats.

Beyond its scientific innovation, the Moderna vaccine had significant implications for global vaccination strategies. Its high efficacy in preventing severe disease and hospitalization helped reduce the burden on healthcare systems worldwide. However, challenges such as ultra-cold chain logistics and public hesitancy toward new vaccine technologies highlighted the need for ongoing education and infrastructure improvements [5, 6]. The vaccine's rollout also underscored inequities in global access, prompting discussions about equitable distribution. As the first widely used mRNA product,

Moderna's vaccine paved the way for broader applications of this technology, potentially transforming how future vaccines are designed and deployed [2, 4]. Its impact extends beyond the pandemic, offering a blueprint for rapid response to emerging pathogens.

2. Properties and Structure

2.1 Vaccine Type and Delivery System

The Moderna COVID-19 vaccine belongs to a novel class of mRNA vaccines that employ lipid nanoparticles (LNPs) as delivery systems. Unlike traditional vaccines that use weakened or inactivated pathogens, this vaccine uses synthetic mRNA to instruct human cells to produce viral antigens. The mRNA-1273 vaccine encodes the full-length spike protein of SARS-CoV-2, serving as the primary immunogen, eliciting both neutralizing antibodies and cellular immune responses [1,2].

The LNP delivery system is crucial for protecting the fragile mRNA and facilitating its entry into host cells. Composed of four lipid components—ionizable cationic lipids, phospholipids, cholesterol, and polyethylene glycol (PEG)-lipid conjugates, it ensures both structural integrity and functional efficiency. Ionizable lipids, which are positively charged under acidic conditions, encapsulate negatively charged mRNA during manufacturing and remain neutral at physiological pH to minimize toxicity [7].

Upon intramuscular administration, LNPs fuse with the host cell membranes, allowing mRNA release into the cytoplasm. Ribosomes translate the mRNA into spike proteins, thereby stimulating both humoral and cellular immune responses in the absence of viral replication. The LNP formulation also acts as an adjuvant, enhancing immune recognition [2, 4]. This modular platform allows rapid adaptation to new diseases by changing the mRNA sequence, though it requires strict cold chain storage (-20 ° C) and may cause reactogenicity [2, 7]. Its success has validated mRNA-LNP technology for applications beyond infectious diseases.

2.2 Core Components

The Moderna vaccine's efficacy relies on its core components: synthetic mRNA encoding the SARS-CoV-2 spike protein, lipid nanoparticle (LNP) carriers, and stabilizers. The mRNA is optimized for stability and translation, enabling human cells to transiently produce spike proteins that mimic viral infection without causing disease [1, 2].

LNPs serve as delivery vehicles, comprising ionizable cationic lipids (binding mRNA), helper lipids (phospholipids and cholesterol for structure), and PEG-lipid conjugates (stabilizing particles). Ionizable lipids exhibit pH-responsive charge behavior—positive during formulation for RNA encapsulation and neutral in systemic circulation to reduce toxicity [3, 7].

Stabilizers like sucrose and NaCl maintain formulation integrity. Sucrose acts as a cryoprotectant during freezing, while NaCl maintains osmotic and pH balance, which is critical for cold chain storage [8]. This modular design allows rapid adaptation to variants by updating mRNA sequences, leveraging consistent LNP delivery and stabilizers [2, 4].

2.3 Structural Optimization

The Moderna vaccine's structure balances stability and functionality. The mRNA encoding the SARS-CoV-2 spike protein is optimized with pseudouridine and optimized untranslated regions (UTRs) to enhance stability and translation [1, 2]. Its secondary structure, optimized through computational modeling, resists enzymatic degradation, though thermostability improvements remain a research focus.

Encapsulated in 80-100 nm lipid nanoparticles (LNPs), the mRNA is shielded by a shell of ionizable lipids, phospholipids, cholesterol, and PEGylated lipids [7]. This design enables endosomal escape and mRNA release into the cytoplasm, where ribosomes translate it into spike proteins. LNPs

also act as adjuvants, stimulating immune recognition [2]. Ongoing research aims to optimize lipid formulations and mRNA structure for improved stability and reduced reactogenicity [3, 4].

3. Clinical Efficacy

3.1 Phase III COVE Trial Results

The Phase III COVE trial established the efficacy of Moderna's mRNA-1273 vaccine. It enrolled over 30,000 participants across diverse demographics — including adults aged 18-85+, ethnic minorities, and individuals with comorbidities—to evaluate real-world protection [1, 2]. Interim results showed >90% efficacy against symptomatic COVID-19, with consistent performance across age groups (e.g., 91.3% efficacy in individuals aged≥65) and high-risk populations like healthcare workers [9]. Notably, the vaccine reduced hospitalization rates by 95% and severe disease cases (e.g., intubation needs) by 98%, significantly alleviating healthcare system burdens. Long-term follow-up (12+ months) documented stable antibody titers and durable T-cell responses, while safety assessments confirmed transient local/reactogenic effects in 85% of recipients and rare myocarditis (0.0012%) primarily in adolescent males [10]. The trial's robust design—including randomized, double-blind, placebo-controlled protocols and real-time variant surveillance—validated its broad applicability and set a standard for evaluating COVID-19 vaccine efficacy.

3.2 Efficacy Against Variants

The emergence of SARS-CoV-2 variants challenged vaccine efficacy, with Moderna's mRNA-1273 showing reduced neutralization against Alpha/Delta [6, 9]. While protection against severe disease remained robust due to preserved T-cell responses [2], efficacy against mild-to-moderate infections declined, particularly against Delta. Laboratory studies indicated that neutralizing antibody titers against Delta dropped by 6 to 10-fold compared to the wild-type virus, though CD4+ and CD8+ T cell responses remained intact.

Omicron's mutations caused the most significant antibody evasion, but booster doses restored protection by increasing titers and broadening immune recognition [6]. Real-world data showed boosted individuals had lower symptomatic infection and hospitalization rates during the Omicron waves [9]. Though breakthrough infections occurred, the vaccine-maintained effectiveness against severe outcomes [2]. Booster durability and optimal dosing intervals continue to be refined [6], with ongoing trials evaluating 3-month vs. 6-month intervals and the impact of variant-specific boosters on long-term immunity.

3.3 Immune Durability

The Moderna vaccine's immune protection demonstrates a pattern of initially robust, but gradually waning, neutralizing antibody titers within six months. Initial high antibody levels peak weeks after vaccination but naturally wane, stabilizing at lower levels by month three [4]. However, long-lived memory B cells and T cells form a lasting defense: memory B cells rapidly produce antibodies upon re-exposure, while memory T cells target infected cells [2]. Importantly, these memory cells exhibit cross-reactivity with related viruses, contributing to broader protection. Real-world data confirms vaccinated individuals maintain strong protection against severe disease despite antibody decline, with cellular immunity resisting variant evasion [9]. Moreover, the immune memory established by mRNA vaccines may provide a foundation for responding to future viral threats. Booster doses reactivate memory cells, restoring antibody titers and reinforcing long-term immunity [6]. This persistent immune memory highlights the strength of mRNA vaccine platforms in eliciting sustained, durable responses and underscores their potential for shaping the next generation of vaccines.

4. Safety and Side Effects

4.1 Common Reactions

Common reactions to the Moderna vaccine are generally mild, transient, and self-limiting, typically resolving within a few days. These include injection-site pain, fever, fatigue, and myalgia [5, 10]. Injection-site pain is the most common local reaction, presenting as tenderness or swelling, while systemic symptoms like fatigue and myalgia occur more frequently after the second dose and in younger recipients [6, 10]. These flu-like reactions peak within 24-48 hours and reflect normal immune activation, with younger individuals showing heightened reactivity due to stronger immune responses [5]. Despite causing temporary discomfort, these reactions emphasize the vaccine's favorable safety profile. For example, approximately 60% of younger adults reported systemic symptoms after the second dose, all of which resolved without medical intervention [10]. A Ghanaian cohort further showed that 72% of 15+ recipients experienced systemic reactions post-second dose, with females (78%) demonstrating slightly higher reactivity than males (65%), likely due to sex-based differences in immune cell activation and cytokine secretion [5]. These reactions align with robust T-cell and antibody responses, as elevated IL-6 and TNF-α levels transiently drive flu-like symptoms during immune priming [6].

4.2 Rare Adverse Events

While the Moderna vaccine has an overall favorable safety profile, rare risks include anaphylaxis and myocarditis/pericarditis. Anaphylaxis, linked to PEG in LNPs, occurs within minutes to hours post-vaccination and requires post-dose monitoring [11]. Estimated at 2-5 cases per million doses, this severe allergic reaction is managed with epinephrine—for instance, U.S. data shows 3.5 cases/million doses, all stabilized via immediate epinephrine administration. European surveillance data further highlights that 85% of anaphylaxis cases present with cutaneous symptoms (e.g., urticaria, angioedema) alongside respiratory distress, reinforcing the need for 30-minute post-vaccination observation [11].

Myocarditis/pericarditis shows a higher risk in adolescent males and young adults, typically appearing within days after the second dose [10, 12]. Clinical symptoms, such as chest pain or shortness of breath, are generally mild and resolve within weeks, with most patients requiring only supportive care. The absolute risk remains lower than COVID-19-related cardiac complications, reinforcing the vaccine's benefit-to-risk ratio. Ongoing surveillance, such as cardiac biomarker tracking [10], confirms no long-term sequelae in 98% of cases. Mechanistic studies suggest that T-cell-mediated myocardial inflammation may underlie this risk, with male adolescents exhibiting 3-5 times higher incidence (0.0025%) than females, likely due to sex-based differences in immune response regulation [12]. Importantly, SARS-CoV-2 infection carries a tenfold greater risk of myocarditis, reinforcing the vaccine's favorable benefit-to-risk profile.

4.3 Considerations for Special Populations

Special populations require individualized safety considerations for the Moderna vaccine. Data in pregnant women remains limited, though emerging evidence shows no increased risk of adverse pregnancy outcomes compared to unvaccinated groups. The decision to vaccinate during pregnancy involves weighing potential theoretical risks—such as transplacental transfer of components—against the well-documented dangers of COVID-19 during pregnancy, which can include maternal and fetal complications.

For immunocompromised individuals, reduced vaccine efficacy due to impaired immune responses must be weighed against their higher risk of severe COVID-19 [2]. While transplant recipients and those on immunosuppressants often generate weaker antibody responses, partial protection may still offer clinical benefit. Safety profiles in these groups mirror immunocompetent individuals, but monitoring for drug interactions is advised.

Older adults exhibit milder reactogenicity, though age-related immune senescence and comorbidities necessitate careful evaluation [10]. Autoimmune disorder patients face a low risk of vaccine-induced flares, with most maintaining stable disease activity post-vaccination [12]. Caution is warranted for PEG-allergic individuals, while pediatric populations, particularly adolescents, show heightened reactogenicity that aligns with robust immune responses [10]. Ongoing surveillance refines recommendations for these groups, supporting risk-benefit assessments rooted in real-world evidence [1, 2].

5. Combined Application and Limitations

5.1 Heterologous Boosting Strategies

Heterologous boosting with Moderna's mRNA vaccine and inactivated vaccines offers a promising approach to enhance COVID-19 immunity. This strategy combines the broad antigen exposure of inactivated vaccines with the precise spike protein targeting of mRNA technology, eliciting robust immune responses [2, 6]. Safety profiles remain favorable, with reactogenicity similar to homologous mRNA vaccination and no unexpected adverse signals [10]. Immunogenicity studies show enhanced antibody and cellular responses, particularly elevated neutralizing titers against variants, addressing a limitation of inactivated vaccines alone [6]. Practically, it simplifies logistics in regions with limited mRNA access, leverages existing inactivated vaccine stocks, and may reduce hesitancy by serving as a transitional approach to mRNA technology [2]. Key questions remain optimal priming-boosting intervals, durability of protection, and whether alternating platforms in multiple boosters sustains advantages against variants [6]. This approach highlights mRNA technology's adaptability, enabling flexible, safe, and immunogenic combination strategies crucial for addressing global vaccination challenges like variant emergence, waning immunity, and equitable access [2].

5.2 Key Limitations: Cold Chain and Variant Challenges

The Moderna vaccine faces two major limitations affecting real-world use. Strict cold chain requirements (-20° C to -70° C) hinder distribution in resource-limited regions, as mRNA instability requires specialized freezers. While recent formulations extend shelf life at standard refrigeration, initial cold chain demands disproportionately impact developing countries with limited infrastructure.

Variant antigenic drift is another challenge: SARS-CoV-2 spike mutations (e.g., Omicron) evade vaccine-induced antibodies, increasing breakthrough infections [6]. Though protection against severe disease remains high, reduced efficacy against symptomatic cases allows community transmission. The need for constant reformulation to match variant strains poses public health implementation challenges.

These limitations compound globally: regions lacking cold storage lag in accessing updated vaccines, risking vulnerability during variant surges and eroding public confidence [2]. Future research focuses on thermostable mRNA formulations (via optimized LNP and mRNA structures) [3] and multivalent vaccines targeting conserved viral epitopes to address both issues.

6. Conclusion

The Moderna COVID-19 vaccine represents a revolutionary milestone in vaccine technology, demonstrating the immense potential of mRNA-based platforms. By using lipid nanoparticles (LNPs) to deliver genetic instructions for spike protein production, this innovative approach has elicited robust immune responses against SARS-CoV-2, with clinical trials confirming high efficacy in preventing severe disease and a favorable safety profile with mostly transient side effects. This success has validated mRNA technology as a viable and transformative platform for vaccine development. However, challenges remain, including strict cold chain requirements (-20° C to -70°

C) that hinder global accessibility, particularly in resource-limited regions, and antigenic drift in viral variants that necessitate ongoing formulation updates to maintain efficacy. Looking ahead, mRNA technology holds promise for advancements such as thermostable formulations to eliminate cold chain barriers, mucosal immunization routes (e.g., intranasal delivery), multivalent vaccines against variants, and expansions into cancer immunotherapy. The Moderna vaccine's legacy extends beyond COVID-19, establishing mRNA platforms as a cornerstone of 21st-century preventive medicine for their speed, precision, and adaptability to evolving health threats.

References

[1] Brett Leav, Walter Straus, Phil White, et al. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273) [J]. Vaccine, 2022, (40):5275-5293.

[2] Mona Sadat Mirtaleb, Reza Falak, Jalal Heshmatnia, et al. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations[J]. International Immunopharmacology, 2023, (117).

[3] Xiangfei Shan, Renji Gu, Yufei Xia, et al. Exploring the role of cationic lipids in modulating immunogenicity and vaccine efficacy of mRNA-LNP[J]. Particuology, 2025, (97):1-11.

[4] Mona Sadat Mirtaleb, Reza Falak, Jalal Heshmatnia, et al. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations[J]. International Immunopharmacology, 2023, (117).

[5] Delese Mimi Darko, Seth Kwaku Seaneke, Eric Karikari-Boateng, et al. Safety of mRNA COVID-19 vaccines among persons 15 years and above in Ghana: A cohort event monitoring study[J]. Vaccine, 2024, (2).

[6] Ying-Chyi Song, Shih-Jen Liu, Hui-Ju Lee, et al. Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis[J]. Journal of Microbiology, Immunology and Infection, 2023, (56):705-717.

[7] Kimberly J. Hassett, Jaclyn Higgins, Angela Woods, et al. Effect of lipid nanoparticle size on mRNA vaccine immunogenicity[J]. Journal of Controlled Release, 2021, (335):237-246.

[8] P. Nesvadba, M. Houška, W. Wolf, et al. Database of physical properties of agro-food materials[J]. Journal of Food Engineering, 2004, (61).

[9] George N. Ioannou, Emily R. Locke, Pamela K. Green, et al. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system[J]. eClinical Medicine, 2022, (3).

[10] Suminobu Ito, Nao Tsuchida, Susumu Kusunoki, et al. Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan[J]. Vaccine, 2025, (1).

[11] Hannah N. Haq, Hafiz Khan, Haroon Chaudhry, et al. Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions[J]. Journal of the National Medical Association, 2022, (6):612-612.

[12] Mashood Badshah, Jackson Shriver, Beatrice Rynders, et al. MODERNA mRNA-1273 vaccine-associated myopericarditis in a patient with a subclinical autoimmune predisposition[J]. Journal of Cardiology Cases, 2021, (24):227-229.